Current Heart Failure Reports

, Volume 13, Issue 1, pp 1–12 | Cite as

Comorbidities in Heart Failure: Are There Gender Differences?

  • Ingrid Hopper
  • Dipak Kotecha
  • Ken Lee Chin
  • Robert J. Mentz
  • Thomas G. von LuederEmail author
Comorbidities of Heart Failure (C Angermann, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Comorbidities of Heart Failure


Compared to men, women with heart failure (HF) are often older, smoke less, and have more preserved ejection fraction (EF) and hypertensive HF rather than HF of ischemic etiology. Gender-stratified outcomes on comorbidities data in HF are scarce. Women have traditionally been underrepresented in HF trials. Although data suggest that overall prognosis may be better in women, they experience lower quality of life with greater functional impairment from HF compared to men. Gender differences have been reported for comorbid diabetes, chronic obstructive pulmonary disease, renal dysfunction, anemia, and depression and may explain gender disparity in outcomes. However, possible confounding of comorbidities with known prognostic determinants in HF (such as EF) as well as gender differences in the utilization of medical therapies obscures interpretation. In this review, we will explore the evidence for gender differences in non-cardiovascular comorbidities in HF. Our findings may guide clinicians to individualize HF care, according to best practice, in the hope of improving prognosis for this chronic and debilitating condition.


Heart failure Ejection fraction Comorbidity Diabetes Anemia COPD Renal dysfunction Arthritis 


Compliance with Ethical Standards

Conflict of Interest

Robert Mentz receives research support from the NIH, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Otsuka, and ResMed; honoraria from HeartWare, Janssen, Luitpold Pharmaceuticals, Novartis, ResMed, and Thoratec; and has served on an advisory board for Luitpold Pharmaceuticals, Inc.

Thomas von Lueder has received research support from the South-Eastern Norwegian Health Authority and honoraria from Novartis and has served on advisory boards for Vifor and Novartis.

Dipak Kotecha has received professional development support from Daiitchi Sankyo, research grants from Menarini, and is the Lead for the Beta-blockers in Heart Failure Collaborative Group (BB-meta-HF).

Ingrid Hopper and Ken Lee Chin report no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.•
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292. This paper provides important statistical data on heart failure and other cardiovascular diseases.PubMedCrossRefGoogle Scholar
  2. 2.
    Ahluwalia SC, Gross CP, Chaudhry SI, Leo-Summers L, Van Ness PH, Fried TR. Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med. 2011;26(10):1145–51.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Page 2nd RL, Lindenfeld J. The comorbidity conundrum: a focus on the role of noncardiovascular chronic conditions in the heart failure patient. Curr Cardiol Rep. 2012;14(3):276–84.PubMedCrossRefGoogle Scholar
  4. 4.••
    Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–93. This work provides the best currently available overview over the prevalence and impact of non-cardiac comorbidities on outcomes in patients with HFpEF versus HFrEF.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet. 2003;362(9378):147–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Ahluwalia SC, Gross CP, Chaudhry SI, Ning YM, Leo-Summers L, Van Ness PH, et al. Impact of comorbidity on mortality among older persons with advanced heart failure. J Gen Intern Med. 2012;27(5):513–9.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.••
    Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71. The authors present a novel and plausible paradigm for HFpEF, underscoring the pathophysiological importance of comorbidities.PubMedCrossRefGoogle Scholar
  9. 9.
    Wong CM, Hawkins NM, Petrie MC, Jhund PS, Gardner RS, Ariti CA, et al. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). Eur Heart J. 2014;35(39):2714–21.PubMedCrossRefGoogle Scholar
  10. 10.•
    Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. This paper presents comprehensive and contemporary data on heart failure and the importance of comorbidities in a well-defined population.PubMedCrossRefGoogle Scholar
  11. 11.
    Klempfner R, Koifman E, Goldenberg I, Hamdan A, Tofler GH, Kopel E. The Israel Nationwide Heart Failure Survey: sex differences in early and late mortality for hospitalized heart failure patients. J Card Fail. 2014;20(3):193–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Brandsaeter B, Atar D, Agewall S. Gender differences among Norwegian patients with heart failure. Int J Cardiol. 2011;146(3):354–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Adams Jr KF, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28(7):1781–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Alla F, Al-Hindi AY, Lee CR, Schwartz TA, Patterson JH, Adams Jr KF. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. Am Heart J. 2007;153(6):1074–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Tasevska-Dinevska G, Kennedy LM, Nilsson PM, Willenheimer R. Gender aspects on heart failure incidence and mortality in a middle-aged, urban, community-based population sample: the Malmo preventive project. Eur J Epidemiol. 2009;24(5):249–57.PubMedCrossRefGoogle Scholar
  16. 16.
    Conde-Martel A, Arkuch ME, Formiga F, Manzano-Espinosa L, Aramburu-Bodas O, Gonzalez-Franco A, Davila-Ramos MF, Suarez-Pedreira I, Herrero-Domingo A, Montero-Perez-Barquero M. Gender related differences in clinical profile and outcome of patients with heart failure. Results of the RICA Registry. Rev Clin Esp 2015.Google Scholar
  17. 17.
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). Am J Cardiol. 2009;104(1):107–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol. 2003;42(12):2128–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008;10(2):140–8.PubMedCrossRefGoogle Scholar
  20. 20.•
    Cui X, Kaspar M, Zhu H, Stork S, Ertl G, Zhou J, et al. Clinical characteristics, treatment and survival in patients with systolic heart failure—comparative assessment of a Chinese and a German cohort. Int J Cardiol. 2014;176(3):1388–90. This work provides important insights into heart failure and comorbidities in two well-characterized distinct ethnic cohorts.PubMedCrossRefGoogle Scholar
  21. 21.
    Adams Jr KF, Sueta CA, Gheorghiade M, O’Connor CM, Schwartz TA, Koch GG, et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation. 1999;99(14):1816–21.PubMedCrossRefGoogle Scholar
  22. 22.
    O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Pina IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2007;115(24):3111–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, et al. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). Am J Cardiol. 2012;110(12):1803–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Martinez-Selles M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail. 2012;14(5):473–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol. 2010;105(8):1140–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47(1):76–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Klein L, Grau-Sepulveda MV, Bonow RO, Hernandez AF, Williams MV, Bhatt DL, et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail. 2011;4(5):589–98.PubMedCrossRefGoogle Scholar
  28. 28.•
    von Lueder TG, Atar D. Comorbidities and polypharmacy. Heart Fail Clin. 2014;10(2):367–72. This manuscript discusses the interdependence of comorbidities and polypharmacy in heart failure.CrossRefGoogle Scholar
  29. 29.••
    Chamberlain AM, St Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, et al. Multimorbidity in heart failure: a community perspective. Am J Med. 2015;128(1):38–45. The authors of this most relevant work provide contemporary data on the significance of comorbidities for mortality and morbidity in the community.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRefGoogle Scholar
  31. 31.
    Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Galvao M, Kalman J, DeMarco T, Fonarow GC, Galvin C, Ghali JK, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail. 2006;12(2):100–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43(5):771–7.PubMedCrossRefGoogle Scholar
  34. 34.••
    Meyer S, van der Meer P, Massie BM, O’Connor CM, Metra M, Ponikowski P, et al. Sex-specific acute heart failure phenotypes and outcomes from PROTECT. Eur J Heart Fail. 2013;15(12):1374–81. This is a very important manuscript on gender and its relation to outcomes in patients with acute heart failure.PubMedCrossRefGoogle Scholar
  35. 35.
    Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3(2):136–45.PubMedCrossRefGoogle Scholar
  36. 36.
    Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Hsich EM, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Schwamm LH, Bhatt DL, et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. Am Heart J. 2012;163(3):430–7. 437 e1-3.PubMedCrossRefGoogle Scholar
  38. 38.
    Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation. 2001;103(3):375–80.PubMedCrossRefGoogle Scholar
  40. 40.••
    Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012;5(5):571–8. This highly relevant work shows gender-specific data for diabetes and other comorbidities in a predominantly female HFpEF cohort.PubMedCrossRefGoogle Scholar
  41. 41.
    Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Tadaki S, et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. Circ J. 2014;78(2):428–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Jimenez-Navarro MF, Munoz Garcia AJ, Garcia-Pinilla JM, Gomez Hernandez G, Gomez-Doblas JJ, de Teresa Galvan E. Trends of hospitalizations for chronic heart failure in Andalusia in the last decade. Rev Clin Esp. 2006;206(10):474–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–39.PubMedCrossRefGoogle Scholar
  44. 44.
    Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113(23):2713–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Krum H, Iyngkaran P, Lekawanvijit S. Pharmacologic management of the cardiorenal syndrome in heart failure. Curr Heart Fail Rep. 2009;6(2):105–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Mentz RJ, Lewis EF. Epidemiology of cardiorenal syndrome. Heart Fail Clin. 2010;6(3):333–46.PubMedCrossRefGoogle Scholar
  47. 47.••
    Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes. 2013;6(3):333–42. This study provides important data on the detrimental effects of reduced kidney function on outcome in heart failure.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Waldum B, Westheim AS, Sandvik L, Flonaes B, Grundtvig M, Gullestad L, et al. Renal function in outpatients with chronic heart failure. J Card Fail. 2010;16(5):374–80.PubMedCrossRefGoogle Scholar
  49. 49.••
    Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235–43. This article is the largest analysis of the effect of atrial fibrillation on pharmacotherapy in heart failure.PubMedCrossRefGoogle Scholar
  50. 50.
    Cleland JG, Carubelli V, Castiello T, Yassin A, Pellicori P, Antony R. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev. 2012;17(2):133–49.PubMedCrossRefGoogle Scholar
  51. 51.
    Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMedCrossRefGoogle Scholar
  53. 53.
    Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, et al. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J. 2009;157(4):754–62. e2.PubMedCrossRefGoogle Scholar
  54. 54.
    Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39(11):1780–6.PubMedCrossRefGoogle Scholar
  55. 55.
    van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8(9):485–93.PubMedCrossRefGoogle Scholar
  56. 56.
    Ezekowitz JA, McAlister FA, Armstrong PW. The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. Can J Cardiol. 2005;21(2):165–71.PubMedGoogle Scholar
  57. 57.
    Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation. 2003;107(2):223–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008;13(4):387–92.PubMedCrossRefGoogle Scholar
  59. 59.
    Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113(20):2454–61.PubMedCrossRefGoogle Scholar
  60. 60.
    Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818–27.PubMedCrossRefGoogle Scholar
  61. 61.
    O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2006;113(7):986–94.PubMedCrossRefGoogle Scholar
  62. 62.
    Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101(2):223–30.PubMedCrossRefGoogle Scholar
  63. 63.
    Le Jemtel TH, Arain S. Mediators of anemia in chronic heart failure. Heart Fail Clin. 2010;6(3):289–93.PubMedCrossRefGoogle Scholar
  64. 64.
    Rangel I, Goncalves A, de Sousa C, Leite S, Campelo M, Martins E, et al. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology. 2014;128(4):320–6.PubMedCrossRefGoogle Scholar
  65. 65.•
    Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16(9):984–91. The authors provide a nice overview on anemia and iron deficiency in heart failure.PubMedCrossRefGoogle Scholar
  66. 66.
    Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011;161(5):822–31. e2.PubMedCrossRefGoogle Scholar
  67. 67.
    Waldum B, Westheim AS, Sandvik L, Flonaes B, Grundtvig M, Gullestad L, et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol. 2012;59(4):371–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872–80.PubMedCrossRefGoogle Scholar
  70. 70.
    Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241–51.PubMedCrossRefGoogle Scholar
  71. 71.
    Afilalo J. Frailty in patients with cardiovascular disease: why, when, and how to measure. Curr Cardiovasc Risk Rep. 2011;5(5):467–72.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.•
    McNallan SM, Singh M, Chamberlain AM, Kane RL, Dunlay SM, Redfield MM, et al. Frailty and healthcare utilization among patients with heart failure in the community. JACC Heart Fail. 2013;1(2):135–l. This paper, although not gender specific, presents evidence on the significance of frailty as a comorbidity to heart failure.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009;103(11):1616–21.PubMedCrossRefGoogle Scholar
  74. 74.
    Goldwater DS, Pinney SP. Frailty in advanced heart failure: a consequence of aging or a separate entity? Clin Med Insights Cardiol. 2015;9 Suppl 2:39–46.PubMedCentralPubMedGoogle Scholar
  75. 75.
    McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL, Weston SA, et al. Measuring frailty in heart failure: a community perspective. Am Heart J. 2013;166(4):768–74.PubMedCrossRefGoogle Scholar
  76. 76.
    Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014;63(8):747–62.PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Ann Epidemiol. 2013;23(2):80–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Rahman MM, Kopec JA, Anis AH, Cibere J, Goldsmith CH. Risk of cardiovascular disease in patients with osteoarthritis: a prospective longitudinal study. Arthritis Care Res. 2013;65(12):1951–8.CrossRefGoogle Scholar
  79. 79.
    Thomas E, Peat G, Harris L, Wilkie R, Croft PR. The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). Pain. 2004;110(1–2):361–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open 2013;3(5).Google Scholar
  81. 81.
    Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I Arthritis Rheum. 2008;58(1):15–25.PubMedCrossRefGoogle Scholar
  82. 82.
    Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum. 2008;58(1):26–35.PubMedCrossRefGoogle Scholar
  83. 83.
    Lacey RJ, Thomas E, Duncan RC, Peat G. Gender difference in symptomatic radiographic knee osteoarthritis in the Knee Clinical Assessment—CAS(K): a prospective study in the general population. BMC Musculoskelet Disord. 2008;9:82.PubMedCentralPubMedCrossRefGoogle Scholar
  84. 84.
    Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991–94. J Rheumatol. 2006;33(11):2271–9.PubMedGoogle Scholar
  85. 85.
    Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–72.PubMedGoogle Scholar
  86. 86.
    Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679–87. e1.PubMedCrossRefGoogle Scholar
  87. 87.
    Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48 Suppl 2:ii2–8.CrossRefGoogle Scholar
  88. 88.
    Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, et al. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009;11(6):542–50.PubMedCrossRefGoogle Scholar
  89. 89.
    Davis III JM, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 2008;58(9):2603–11.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777–84.PubMedCrossRefGoogle Scholar
  91. 91.
    De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16(3):225–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J. 1999;138(5 Pt 1):835–42.PubMedCrossRefGoogle Scholar
  93. 93.•
    Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res. 2013;162(4):208–18. Here the authors describe the prevalence of COPD in men than in women although no major link to heart failure is provided.PubMedCrossRefGoogle Scholar
  94. 94.
    Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013;162(4):237–51.PubMedCrossRefGoogle Scholar
  95. 95.
    Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119(6):1691–5.PubMedCrossRefGoogle Scholar
  96. 96.•
    Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10(1):24. The study in subjects with COPD shows a higher prevalence of HF in women than in men.PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O’Connor CM. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? J Card Fail. 2012;18(5):413–22.PubMedCrossRefGoogle Scholar
  99. 99.
    Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527–37.PubMedCrossRefGoogle Scholar
  100. 100.
    Angermann CE, Gelbrich G, Stork S, Schowalter M, Deckert J, Ertl G, et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. Int J Cardiol. 2011;147(1):66–73.PubMedCrossRefGoogle Scholar
  101. 101.
    Faller H, Stork S, Schowalter M, Steinbuchel T, Wollner V, Ertl G, et al. Depression and survival in chronic heart failure: does gender play a role? Eur J Heart Fail. 2007;9(10):1018–23.PubMedCrossRefGoogle Scholar
  102. 102.
    Krum H, Iyngkaran P. The black dog and the weak heart: comorbid depression in the patient with heart failure. J Card Fail. 2008;14(6):465–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Lesman-Leegte I, Jaarsma T, Sanderman R, Hillege HL, van Veldhuisen DJ. Determinants of depressive symptoms in hospitalised men and women with heart failure. Eur J Cardiovasc Nurs. 2008;7(2):121–6.PubMedCrossRefGoogle Scholar
  104. 104.
    McGann PE. Comorbidity in heart failure in the elderly. Clin Geriatr Med. 2000;16(3):631–48.PubMedCrossRefGoogle Scholar
  105. 105.•
    Wallenborn J, Angermann CE. Comorbid depression in heart failure. Herz. 2013;38(6):587–96. This work constitutes a recent overview of the significance of comorbid depression in heart failure.PubMedCrossRefGoogle Scholar
  106. 106.
    Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993;270(15):1819–25.PubMedCrossRefGoogle Scholar
  107. 107.
    Moudgil R, Haddad H. Depression in heart failure. Curr Opin Cardiol. 2013;28(2):249–58.PubMedCrossRefGoogle Scholar
  108. 108.
    Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry. 1997;58 Suppl 15:12–8.PubMedGoogle Scholar
  109. 109.
    Farrell K, Shen BJ, Mallon S, Penedo FJ, Antoni MH. Utility of the Millon Behavioral Medicine Diagnostic to predict medication adherence in patients diagnosed with heart failure. J Clin Psychol Med Settings. 2011;18(1):1–12.PubMedCrossRefGoogle Scholar
  110. 110.
    Hamilton MA. Prevalence and clinical implications of abnormal thyroid hormone metabolism in advanced heart failure. Ann Thorac Surg. 1993;56(1 Suppl):S48–52. discussion S52-3.PubMedCrossRefGoogle Scholar
  111. 111.
    Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Goldman S, Thomson S, McCarren M. Clinical implications of abnormal thyroid function in heart failure. JACC Heart Fail. 2013;1(1):56–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Roos A, Links TP, Wolffenbuttel BH. Subclinical thyroid disease and heart failure. Eur J Heart Fail. 2014;16(2):119–21.PubMedCrossRefGoogle Scholar
  114. 114.
    Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, et al. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol. 2005;288(5):H2118–22.PubMedCrossRefGoogle Scholar
  115. 115.
    d’Amati G, di Gioia CR, Mentuccia D, Pistilli D, Proietti-Pannunzi L, Miraldi F, et al. Increased expression of thyroid hormone receptor isoforms in end-stage human congestive heart failure. J Clin Endocrinol Metab. 2001;86(5):2080–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Inglis SC, Bebchuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, et al. Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. Int J Cardiol. 2013;168(2):1094–101.PubMedCrossRefGoogle Scholar
  117. 117.
    Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–43.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ingrid Hopper
    • 1
    • 2
  • Dipak Kotecha
    • 1
    • 3
  • Ken Lee Chin
    • 1
    • 2
  • Robert J. Mentz
    • 4
  • Thomas G. von Lueder
    • 1
    • 5
    Email author
  1. 1.Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive MedicineMonash University, Alfred HospitalMelbourneAustralia
  2. 2.Clinical Pharmacology DepartmentAlfred HealthMelbourneAustralia
  3. 3.University of Birmingham Institute of Cardiovascular SciencesBirminghamUK
  4. 4.Duke UniversityDurhamUSA
  5. 5.Department of CardiologyOslo University Hospital UllevålOsloNorway

Personalised recommendations